+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Europe Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II), Indication (Oncology, Diabetes), Study Design, Service Type, Sponsor, Region, and Segment Forecasts, 2025-2030- Product Image
Europe Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II), Indication (Oncology, Diabetes), Study Design, Service Type, Sponsor, Region, and Segment Forecasts, 2025-2030- Product Image
New

Europe Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II), Indication (Oncology, Diabetes), Study Design, Service Type, Sponsor, Region, and Segment Forecasts, 2025-2030

  • PDF Icon

    Report

  • 120 Pages
  • October 2024
  • Region: Europe
  • Grand View Research
  • ID: 5569685
Description Jump to:
The Europe clinical trials market size is expected to reach USD 32.43 billion by 2030. The market is expected to expand at a CAGR of 6.86% from 2025 to 2030. The rise in technological advancement for clinical trials is one of the key factors driving the market. The growing adoption of new technologies like artificial intelligence, big data analytics, blockchain, clinical trials payments, and patient engagement solutions among others have significantly contributed to the market growth. The COVID-19 pandemic had improved the adoption of virtual clinical trials in the region. Therefore, the growing adoption of new technologies is likely to promote the growth of the market.

The demand for personalized medicines has significantly improved in the region owing to significant research funding for personalized therapies by the European Commission. The aim of various countries in Europe is to collaborate research and health policy to accelerate the adoption of personalized medicine with the formation of the International Consortium for Personalized Medicine, which brings together health research funders and policymaking groups. Such activities are likely to promote market growth. The region suffers from growing disease variation and prevalence. A significant number of people in the region suffer from chronic and rare diseases.

For instance, the European Commission states that approximately 5,000-8,000 distinct rare diseases affect around 6-8% of the European population i.e., between 27 - 36 million. Thus, the high burden of rare diseases is likely to increase the demand for researchers to develop therapeutics for rare diseases. The rising cost associated with research studies has increased the demand for CROs in the region for conducting clinical trials. The partnership agreement between pharmaceutical companies and CROs is likely to promote market growth.

Europe was one the worst affected region by the COVID-19 pandemic, owing to which public organizations in the region made significant funding in research to boost the development of COVID-19 vaccines and diagnostics. For instance, in June 2020 the French president pledged to invest USD 679 million to support the development of COVID-19 vaccines. Owing to the pandemic several research centers were shut down due to the national lockdown implemented by the government authorities, owing to which several clinical trial organizations opted for in silico trials and virtual clinical trials to speed up the research process. Such actions had profited the growth of the market.

Europe Clinical Trials Market Report Highlights

  • The phase I trial segment is projected to witness a remarkable growth rate of 7.49% over the forecast period. This can be attributed to the significant R&D spending by public and private organizations to support new researches
  • The interventional study design segment held the largest market share of 80.57% in 2024 owing to the greater accuracy offered by these studies, as compared to other clinical study designs
  • European countries such as Germany and the U.K. are spearheading the revenue share, as these have a large patient pool and the presence of advanced medical infrastructure

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments
  • Competitive Landscape: Explore the market presence of key players worldwide
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

The leading players in the Europe Clinical Trials market include:

  • IQVIA HOLDINGS, INC.
  • PAREXEL International Corporation
  • Pharmaceutical Product Development (PPD) LLC.
  • Syneos Health Inc.
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Dr. Notghi Contract Research GmbH
  • Charite Research Organisation GmbH
  • Janssen Global Services, LLC
  • Mondosano GmbH
  • KFGN
  • Clariness
  • Invisio clinical studies consulting


This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Study Design
1.2.2. Phase
1.2.3. Indication
1.2.4. Service Type
1.2.5. Sponsor
1.3. Regional Scope
1.4. Estimates And Forecast Timeline
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Bottom-up Approach
1.10. List Of Secondary Sources
1.11. List Of Abbreviations
1.12. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Europe Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing adoption of new technology in clinical research
3.2.1.2. Shift toward personalized medicine
3.2.1.3. Growing disease variation and prevalence
3.2.1.4. Growth in CRO market
3.2.2. Market Restraint Analysis
3.2.2.1. Regulations in new drug development
3.2.2.2. Pricing pressure
3.3. Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. Analysis of total number of clinical trial studies conducted, by countries
3.3.4. Cost breakdown analysis for CRO's
3.3.5. Percent of outsourced vs in-house clinical trial categories
3.3.6. Cost breakdown analysis for CRO's by Phase I, II, & III
3.3.7. COVID-19 Impact Analysis
Chapter 4. Europe Clinical Trials Market: Phase Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Europe Clinical Trials Market, Phase Movement Analysis
4.3. Europe Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
4.4. Phase I
4.4.1. Phase I Market, 2018 to 2030 (USD Million)
4.5. Phase II
4.5.1. Phase II Market, 2018 to 2030 (USD Million)
4.6. Phase III
4.6.1. Phase III Market, 2018 to 2030 (USD Million)
4.7. Phase IV
4.7.1. Phase IV Market, 2018 to 2030 (USD Million)
Chapter 5. Europe Clinical Trials Market: Study Design Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Europe Clinical Trials Market, Study Design Movement Analysis
5.3. Europe Clinical Trials Size & Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
5.4. Interventional studies
5.4.1. Interventional Studies Market, 2018 to 2030 (USD Million)
5.5. Observational studies
5.5.1. Observational Studies Market, 2018 to 2030 (USD Million)
5.6. Expanded access studies
5.6.1. Expanded Access Studies Market, 2018 to 2030 (USD Million)
Chapter 6. Europe Clinical Trials Market: Indication Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Europe Clinical Trials Market, Indication Movement Analysis
6.3. Europe Clinical Trials Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
6.4. Autoimmune/inflammation
6.4.1. Autoimmune/Inflammation Market, 2018 to 2030 (USD Million)
6.4.2. Rheumatoid arthritis
6.4.2.1. Rheumatoid Arthritis Market, 2018 to 2030 (USD Million)
6.4.3. Multiple sclerosis
6.4.3.1. Multiple Sclerosis Market, 2018 to 2030 (USD Million)
6.4.4. Osteoarthritis
6.4.4.1. Osteoarthritis Market, 2018 to 2030 (USD Million)
6.4.5. Irritable Bowel Syndrome (IBS)
6.4.5.1. Irritable Bowel Syndrome (IBS) Market, 2018 to 2030 (USD Million)
6.4.6. Others
6.4.6.1. Others Market, 2018 to 2030 (USD Million)
6.5. Pain Management
6.5.1. Pain Management Market, 2018 to 2030 (USD Million)
6.5.2. Chronic Pain
6.5.2.1. Chronic Pain Market, 2018 to 2030 (USD Million)
6.5.3. Acute Pain
6.5.3.1. Acute Pain Market, 2018 to 2030 (USD Million)
6.6. Oncology
6.6.1. Oncology Market, 2018 to 2030 (USD Million)
6.6.2. Blood Cancer
6.6.2.1. Blood Cancer Market, 2018 to 2030 (USD Million)
6.6.3. Solid Tumors
6.6.3.1. Solid Tumors Market, 2018 to 2030 (USD Million)
6.6.4. Other
6.6.4.1. Other Market, 2018 to 2030 (USD Million)
6.7. CNS conditions
6.7.1. CNS Conditions Market, 2018 to 2030 (USD Million)
6.7.2. Epilepsy
6.7.2.1. Epilepsy Market, 2018 to 2030 (USD Million)
6.7.3. Parkinson's Disease (PD)
6.7.3.1. Parkinson's Disease (PD) Market, 2018 to 2030 (USD Million)
6.7.4. Huntington's Disease
6.7.4.1. Huntington's Disease Market, 2018 to 2030 (USD Million)
6.7.5. Stroke
6.7.5.1. Stroke Market, 2018 to 2030 (USD Million)
6.7.6. Traumatic Brain Injury (TBI)
6.7.6.1. Traumatic Brain Injury (TBI) Market, 2018 to 2030 (USD Million)
6.7.7. Amyotrophic Lateral Sclerosis (ALS)
6.7.7.1. Amyotrophic Lateral Sclerosis (ALS) Market, 2018 to 2030 (USD Million)
6.7.8. Muscle Regeneration
6.7.8.1. Muscle Regeneration Market, 2018 to 2030 (USD Million)
6.7.9. Others
6.7.9.1. Other Market, 2018 to 2030 (USD Million)
6.8. Diabetes
6.8.1. Diabetes Market, 2018 to 2030 (USD Million)
6.9. Obesity
6.9.1. Obesity Market, 2018 to 2030 (USD Million)
6.10. Cardiovascular
6.10.1. Cardiovascular Market, 2018 to 2030 (USD Million)
6.11. Others
6.11.1. Others Market, 2018 to 2030 (USD Million)
Chapter 7. Europe Clinical Trials Market: Service Type Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Europe Clinical Trials Market, Service Type Movement Analysis
7.3. Europe Clinical Trials Size & Trend Analysis, by Service Type, 2018 to 2030 (USD Million)
7.4. Protocol Designing
7.4.1. Protocol Designing Market, 2018 to 2030 (USD Million)
7.5. Site Identification
7.5.1. Site Identification Market, 2018 to 2030 (USD Million)
7.6. Patient Recruitment
7.6.1. Patient Recruitment Market, 2018 to 2030 (USD Million)
7.7. Laboratory Services
7.7.1. Laboratory Services Market, 2018 to 2030 (USD Million)
7.8. Bioanalytical Testing Services
7.8.1. Bioanalytical Testing Services Market, 2018 to 2030 (USD Million)
7.9. Clinical Trial Data Management Services
7.9.1. Clinical Trial Data Management Services Market, 2018 to 2030 (USD Million)
7.10. Others
7.10.1. Others Market, 2018 to 2030 (USD Million)
Chapter 8. Europe Clinical Trials Market: Sponsor Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Europe Clinical Trials Market, Sponsor Movement Analysis
8.3. Europe Clinical Trials Size & Trend Analysis, by Sponsor, 2018 to 2030 (USD Million)
8.4. Pharmaceutical & biopharmaceutical companies
8.4.1. Protocol Designing Market, 2018 to 2030 (USD Million)
8.5. Medical device companies
8.5.1. Protocol Designing Market, 2018 to 2030 (USD Million)
8.6. Others
8.6.1. Others Market, 2018 to 2030 (USD Million)
Chapter 9. Europe Clinical Trials Market: Regional Estimates & Trend Analysis
9.1. Regional Market Share Analysis, 2024 & 2030
9.2. Regional Market Dashboard
9.3. Europe
9.3.1. Europe Market Estimates and Forecast, 2018-2030 (Revenue, USD Million)
9.3.2. UK
9.3.2.1. Key Country Dynamics
9.3.2.2. Competitive Scenario
9.3.2.3. Regulatory Framework
9.3.2.4. UK Market Estimates and Forecasts, 2018-2030
9.3.3. Germany
9.3.3.1. Key Country Dynamics
9.3.3.2. Competitive Scenario
9.3.3.3. Regulatory Framework
9.3.3.4. Germany Market Estimates and Forecasts, 2018-2030
9.3.4. France
9.3.4.1. Key Country Dynamics
9.3.4.2. Competitive Scenario
9.3.4.3. Regulatory Framework
9.3.4.4. France Market Estimates and Forecasts, 2018-2030
9.3.5. Italy
9.3.5.1. Key Country Dynamics
9.3.5.2. Competitive Scenario
9.3.5.3. Regulatory Framework
9.3.5.4. Italy Market Estimates and Forecasts, 2018-2030
9.3.6. Spain
9.3.6.1. Key Country Dynamics
9.3.6.2. Competitive Scenario
9.3.6.3. Regulatory Framework
9.3.6.4. Spain Market Estimates and Forecasts, 2018-2030
9.3.7. Sweden
9.3.7.1. Key Country Dynamics
9.3.7.2. Competitive Scenario
9.3.7.3. Regulatory Framework
9.3.7.4. Sweden Market Estimates and Forecasts, 2018-2030
9.3.8. Denmark
9.3.8.1. Key Country Dynamics
9.3.8.2. Competitive Scenario
9.3.8.3. Regulatory Framework
9.3.8.4. Denmark Market Estimates and Forecasts, 2018-2030
9.3.9. Norway
9.3.9.1. Key Country Dynamics
9.3.9.2. Competitive Scenario
9.3.9.3. Regulatory Framework
9.3.9.4. Norway Market Estimates and Forecasts, 2018-2030
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Company Market Position Analysis, 2023
10.3. Company Profiles
10.3.1. IQVIA Holdings, Inc.,
10.3.1.1. Company Overview
10.3.1.2. Financial Performance
10.3.1.3. Service Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. Parexel International Corporation
10.3.2.1. Company Overview
10.3.2.2. Financial Performance
10.3.2.3. Service Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. PPD, Inc.
10.3.3.1. Company Overview
10.3.3.2. Financial Performance
10.3.3.3. Service Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. Syneos Health
10.3.4.1. Company Overview
10.3.4.2. Financial Performance
10.3.4.3. Service Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Eli Lilly and Company
10.3.5.1. Company Overview
10.3.5.2. Financial Performance
10.3.5.3. Service Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. Novo Nordisk A/S
10.3.6.1. Company Overview
10.3.6.2. Financial Performance
10.3.6.3. Service Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. Pfizer, Inc.
10.3.7.1. Company Overview
10.3.7.2. Financial Performance
10.3.7.3. Service Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Dr. Notghi Contract Research GmbH
10.3.8.1. Company Overview
10.3.8.2. Financial Performance
10.3.8.3. Service Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Charite Research Organisation GmbH
10.3.9.1. Company Overview
10.3.9.2. Financial Performance
10.3.9.3. Service Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. Janssen Global Services, LLC
10.3.10.1. Company Overview
10.3.10.2. Financial Performance
10.3.10.3. Service Benchmarking
10.3.10.4. Strategic Initiatives
10.3.11. KFGN
10.3.11.1. Company Overview
10.3.11.2. Financial Performance
10.3.11.3. Service Benchmarking
10.3.11.4. Strategic Initiatives
10.3.12. Clariness
10.3.12.1. Company Overview
10.3.12.2. Financial Performance
10.3.12.3. Service Benchmarking
10.3.12.4. Strategic Initiatives
10.3.13. Invisio Clinical Studies Consulting GmbH
10.3.13.1. Company Overview
10.3.13.2. Financial Performance
10.3.13.3. Service Benchmarking
10.3.13.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 1 List of Abbreviations
Table 2 Europe Clinical Trials, by Country, 2018 - 2030 (USD Million)
Table 3 Europe Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 4 Europe Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 5 Europe Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 6 Europe Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 7 Europe Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
Table 8 UK Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 9 UK Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 10 UK Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 11 UK Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 12 UK Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
Table 13 Germany Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 14 Germany Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 15 Germany Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 16 Germany Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 17 Germany Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
Table 18 France Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 19 France Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 20 France Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 21 France Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 22 France Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
Table 23 Italy Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 24 Italy Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 25 Italy Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 26 Italy Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 27 Italy Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
Table 28 Spain Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 29 Spain Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 30 Spain Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 31 Spain Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 32 Spain Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
Table 33 Sweden Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 34 Sweden Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 35 Sweden Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 36 Sweden Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 37 Sweden Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
Table 38 Denmark Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 39 Denmark Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 40 Denmark Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 41 Denmark Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 42 Denmark Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
Table 43 Norway Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 44 Norway Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 45 Norway Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 46 Norway Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 47 Norway Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Europe Clinical Trials Market revenue, 2018 - 2030 (USD Million)
Fig. 10 Europe Clinical Trials Market snapshot
Fig. 11 Europe Clinical Trials Market Driver Impact
Fig. 12 Europe Clinical Trials Market Restraint impact
Fig. 13 Europe Clinical Trials Market: Phase Key Takeaways (USD Million)
Fig. 14 Europe Clinical Trials Market: Phase movement analysis
Fig. 15 Phase I Market, 2018 - 2030 (USD Million)
Fig. 16 Phase II Market, 2018 - 2030 (USD Million)
Fig. 17 Phase III Market, 2018 - 2030 (USD Million)
Fig. 18 Phase IV Market, 2018 - 2030 (USD Million)
Fig. 19 Europe Clinical Trials Product Market: Study Design Key Takeaways (USD Million)
Fig. 20 Europe Clinical Trials Market: Study design movement analysis
Fig. 21 Interventional Studies Market, 2018 - 2030 (USD Million)
Fig. 22 Observational Studies Market, 2018 - 2030 (USD Million)
Fig. 23 Expanded access studies Market, 2018 - 2030 (USD Million)
Fig. 24 Europe Clinical Trials Market: Indication Key Takeaways (USD Million)
Fig. 25 Europe Clinical Trials Market: Indication movement analysis
Fig. 26 Autoimmune/Inflammation Market, 2018 - 2030 (USD Million)
Fig. 27 Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
Fig. 28 Multiple Sclerosis Market, 2018 - 2030 (USD Million)
Fig. 29 Osteoarthritis Market, 2018 - 2030 (USD Million)
Fig. 30 Irritable Bowel Syndrome (IBS) Market, 2018 - 2030 (USD Million)
Fig. 31 Others Market, 2018 - 2030 (USD Million)
Fig. 32 Pain Management Market, 2018 - 2030 (USD Million)
Fig. 33 Chronic pain Market, 2018 - 2030 (USD Million)
Fig. 34 Acute pain Market, 2018 - 2030 (USD Million)
Fig. 35 Oncology Market, 2018 - 2030 (USD Million)
Fig. 36 Blood Cancer Market, 2018 - 2030 (USD Million)
Fig. 37 Solid Tumors Market, 2018 - 2030 (USD Million)
Fig. 38 Other Market, 2018 - 2030 (USD Million)
Fig. 39 CNS conditions Market, 2018 - 2030 (USD Million)
Fig. 40 Epilepsy Market, 2018 - 2030 (USD Million)
Fig. 41 Parkinson's Disease (PD) Market, 2018 - 2030 (USD Million)
Fig. 42 Huntington's Disease Market, 2018 - 2030 (USD Million)
Fig. 43 Stroke Market, 2018 - 2030 (USD Million)
Fig. 44 Traumatic Brain Injury (TBI) Market, 2018 - 2030 (USD Million)
Fig. 45 Amyotrophic Lateral Sclerosis (ALS) Market, 2018 - 2030 (USD Million)
Fig. 46 Muscle regeneration Market, 2018 - 2030 (USD Million)
Fig. 47 Others Market, 2018 - 2030 (USD Million)
Fig. 48 Diabetes Market, 2018 - 2030 (USD Million)
Fig. 49 Obesity Market, 2018 - 2030 (USD Million)
Fig. 50 Cardiovascular Market, 2018 - 2030 (USD Million)
Fig. 51 Others Market, 2018 - 2030 (USD Million)
Fig. 52 Europe Clinical Trials Market: Service Type Key Takeaways (USD Million)
Fig. 53 Europe Clinical Trials Market: Service Type movement analysis
Fig. 54 Protocol Designing Market, 2018 - 2030 (USD Million)
Fig. 55 Site Identification Market, 2018 - 2030 (USD Million)
Fig. 56 Patient Recruitment Market, 2018 - 2030 (USD Million)
Fig. 57 Laboratory Services Market, 2018 - 2030 (USD Million)
Fig. 58 Bioanalytical Testing Services Market, 2018 - 2030 (USD Million)
Fig. 59 Clinical Trial Data Management Services Market, 2018 - 2030 (USD Million)
Fig. 60 Others Market, 2018 - 2030 (USD Million)
Fig. 61 Europe Clinical Trials Market: Sponsor Key Takeaways (USD Million)
Fig. 62 Europe Clinical Trials Market: Sponsor movement analysis
Fig. 63 Pharmaceutical & Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)
Fig. 64 Medical Device Companies Market, 2018 - 2030 (USD Million)
Fig. 65 Others Market, 2018 - 2030 (USD Million)
Fig. 66 Europe Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 67 UK Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 68 Germany Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 69 France Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 70 Italy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 71 Spain companion animal Health market, 2018 - 2030 (USD Million)
Fig. 72 Sweden Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 73 Denmark Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 74 Norway Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 75 Market participant categorization

Companies Mentioned

  • IQVIA HOLDINGS, INC.
  • PAREXEL International Corporation
  • Pharmaceutical Product Development (PPD) LLC.
  • Syneos Health Inc.
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Dr. Notghi Contract Research GmbH
  • Charite Research Organisation GmbH
  • Janssen Global Services, LLC
  • Mondosano GmbH
  • KFGN
  • Clariness
  • Invisio clinical studies consulting

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 22.06 Billion
Forecasted Market Value ( USD ) by 2030 $ 32.43 Billion
Compound Annual Growth Rate6.8%
Regions CoveredEurope
No. of Companies Mentioned14

Related Topics

Related Reports

Atopic Dermatitis Clinical Trials Market Size, Share & Trends Analysis Report by Molecule Type (Small molecules, Large Molecules), Study Designs, Study Phase, Region, and Segment Forecasts, 2024-2030 - Product Image

Atopic Dermatitis Clinical Trials Market Size, Share & Trends Analysis Report by Molecule Type (Small molecules, Large Molecules), Study Designs, Study Phase, Region, and Segment Forecasts, 2024-2030

  • Report
  • 125 Pages
  • Global
From
Clinical Trials Support Services Market Size, Share and Trends Analysis Report by Phase (Phase I, Phase III), Service, Sponsor (Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies), and Region 2024-2030 - Product Image

Clinical Trials Support Services Market Size, Share and Trends Analysis Report by Phase (Phase I, Phase III), Service, Sponsor (Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies), and Region 2024-2030

  • Report
  • 130 Pages
  • Global
From
Virtual Clinical Trials Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 to 2032 - Product Image

Virtual Clinical Trials Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 to 2032

  • Report
  • 170 Pages
  • Global
From
Clinical Trials Market by Design, Phase, Indication - Global Forecast 2025-2030 - Product Image

Clinical Trials Market by Design, Phase, Indication - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Clinical Trial Support Services Market by Service, Phase, Study Design, Indication, Sponsor - Global Forecast 2025-2030 - Product Image

Clinical Trial Support Services Market by Service, Phase, Study Design, Indication, Sponsor - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.